Physiomics (PYC.L) Stock Analysis & Winston Score

Physiomics is a small UK-based biotechnology company that uses computer modeling to help drug developers understand how medicines behave inside the human body. Its main product is a software platform called The Virtual Tumour, which simulates how cancer tumors respond to chemotherapy. Its customers are pharmaceutical and biotech companies that want to improve their drug development process without running as many expensive lab experiments. The company earns money by charging fees for consulting services and software licenses, selling its modeling expertise to clients on a project-by-project basis. Physiomics operates primarily in the UK and serves clients across Europe and North America, but it remains very small, with a market cap close to zero and consistently negative margins. Its competitive edge lies in its specialized scientific knowledge of pharmacokinetic and pharmacodynamic modeling, but the main risk is its heavy reliance on winning enough client contracts to cover costs — the negative gross margin shows it currently spends more than it earns.